Theranostics announced that the Phase 2b trial evaluating RAD101 imaging in brain metastases has achieved 50% patient enrollment ...
Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to ...
6d
ZAP Surgical's ZAP-Axon Radiosurgery Planning System Receives U.S. FDA 510(k) and E.U. CE Clearance
ZAP Surgical Systems, Inc., a pioneer in non-invasive robotic brain surgery, today announced that its award-winning ZAP-Axon(R) Radiosurgery Planning System has received both U.S. FDA 510(k) clearance ...
ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the upcoming installation ...
Stereotactic radiotherapy followed by TTFields treatment led to a 28% relative risk reduction for intracranial progression compared to stereotactic radiotherapy only. Treatment with tumor-treating ...
METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following ...
For Multiple Brain Mets Patients, Significantly Less Healthy Brain Exposed with Dedicated Radiosurgery Devices Compared to Multi-Purpose Radiotherapy Systems ZAP Surgical Systems, Inc., developer of ...
Attendees will have the opportunity to explore a near full-scale model of the ZAP-X system, a dedicated cranial radiosurgery (SRS) innovation that eliminates the need for costly radiation-shielded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback